Simultaneous Determination of Etretinate, Acitretin and 13-cis-Acitretin in Plasma by Gradient-HPLC Using Automated Column Switching

  • R. Wyss
  • F. Bucheli
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 18 A)


Etretinate (Tigason®), an aromatic retinoid ethyl ester, is an oral dermatological drug which is effective in the treatment of psoriasis and other keratinizing disorders [1]. It is hydrolyzed to the corresponding acid in vivo [2]. This metabolite, acitretin, (Neotigason®), has a much shorter elimination half-life and shows the same activity in clinical studies; it will succeed etretinate as a drug in the near future. It furnishes 13-cis-acitretin by isomerization in vivo [2]. Therapeutic drug monitoring is important for this class of compounds because of teratogenicity problems and other side-effects; however, sample handling is difficult in view of the light-sensitivity and the very high protein binding (>99.9%) of the retinoids. Accordingly, an automated method involving gradient elution, column switching and UV detection at 360 nm similar to that described for isotretinoin and its metabolites [3], has been developed for the determination of etretinate, acitretin and 13-cis-acitretirin.


Ammonium Acetate Ethyl Ester Simultaneous Determination Therapeutic Drug Therapeutic Drug Monitoring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Bollag, W. & Hanck, A. (1977) Acta Vitamin. Enzymol. (Milano) 31, 113–123.Google Scholar
  2. 2.
    Paravicini, U., Stoeckel, K., MacNamara, P.J., Haenni, R. & Busslinger, A. (1981) Ann.N.Y. Acad. Sci. 359, 54–67.CrossRefGoogle Scholar
  3. 3.
    Wyss, R. & Bucheli, F. (1988) J. Chrornatog. 424, 303–314.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • R. Wyss
    • 1
  • F. Bucheli
    • 1
  1. 1.Pharmaceutical Research, Preclinical DevelopmentF. Hoffmann-La Roche & Co. Ltd.BaselSwitzerland

Personalised recommendations